Literature DB >> 22851141

Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index.

Nicolai A Schultz1, Klaus K Andersen, Anne Roslind, Hanni Willenbrock, Morten Wøjdemann, Julia S Johansen.   

Abstract

BACKGROUND: The aim of the present study was to identify a panel of microRNAs (miRNAs) that can predict overall survival (OS) in non micro-dissected cancer tissues from patients operated for pancreatic cancer (PC).
METHODS: MiRNAs were purified from formalin-fixed paraffin embedded (FFPE) cancer tissue from 225 patients operated for PC. Only a few of those patients received adjuvant chemotherapy. Expressions of miRNAs were determined with the TaqMan MicroRNA Array v2.0. Two statistical methods, univariate selection and the Lasso (Least Absolute Shrinkage and Selection Operator) method, were applied in conjunction with the Cox proportional hazard model to relate miRNAs to OS.
RESULTS: High expression of miR-212 and miR-675 and low expression of miR-148a, miR-187, and let-7g predicted short OS independent of age, gender, calendar year of operation, KRAS mutation status, tumor stage, American Society of Anesthesiologists (ASA) score, localization (not miR-148a), and differentiation of tumor. A prognostic index (PI) based on these five miRNAs was calculated for each patient. The median survival was 1.09 years (Confidence Interval [CI] 0.98-1.43) for PI > median PI compared to 2.23 years (CI 1.84-4.36) for PI < median. MiR-212, miR-675, miR-187, miR-205, miR-944, miR-431, miR-194, miR-148a, and miR-769-5p showed the strongest prediction ability by the Lasso method. Thus miR-212, miR-675, miR-187, and miR-148a were predictors for OS in both statistical methods.
CONCLUSIONS: The combination of five miRNAs expression in non micro-dissected FFPE PC tissue can identify patients with short OS after radical surgery. The results are independent of chemotherapy treatment. Patients with a prognostic index > median had a very short median OS of only 1 year.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22851141     DOI: 10.1007/s00268-012-1705-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  47 in total

1.  The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis.

Authors:  Naïma Hanoun; Yannick Delpu; Arief A Suriawinata; Barbara Bournet; Christophe Bureau; Janick Selves; Gregory J Tsongalis; Marlène Dufresne; Louis Buscail; Pierre Cordelier; Jérôme Torrisani
Journal:  Clin Chem       Date:  2010-04-29       Impact factor: 8.327

2.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

3.  MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma.

Authors:  Naoki Ikenaga; Kenoki Ohuchida; Kazuhiro Mizumoto; Jun Yu; Tadashi Kayashima; Hiroshi Sakai; Hayato Fujita; Kohei Nakata; Masao Tanaka
Journal:  Ann Surg Oncol       Date:  2010-07-22       Impact factor: 5.344

4.  Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment.

Authors:  Marco Ragusa; Alessandra Majorana; Luisa Statello; Marco Maugeri; Loredana Salito; Davide Barbagallo; Maria Rosa Guglielmino; Laura R Duro; Rosario Angelica; Rosario Caltabiano; Antonio Biondi; Maria Di Vita; Giuseppe Privitera; Marina Scalia; Alessandro Cappellani; Enrico Vasquez; Salvatore Lanzafame; Francesco Basile; Cinzia Di Pietro; Michele Purrello
Journal:  Mol Cancer Ther       Date:  2010-09-29       Impact factor: 6.261

5.  Presentation, treatment and outcome in patients with ampullary tumours.

Authors:  V Bettschart; M Q Rahman; F J F Engelken; K K Madhavan; R W Parks; O J Garden
Journal:  Br J Surg       Date:  2004-12       Impact factor: 6.939

6.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.

Authors:  Mark Bloomston; Wendy L Frankel; Fabio Petrocca; Stefano Volinia; Hansjuerg Alder; John P Hagan; Chang-Gong Liu; Darshna Bhatt; Cristian Taccioli; Carlo M Croce
Journal:  JAMA       Date:  2007-05-02       Impact factor: 56.272

7.  Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.

Authors:  Jin-Hyeok Hwang; Johannes Voortman; Elisa Giovannetti; Seth M Steinberg; Leticia G Leon; Yong-Tae Kim; Niccola Funel; Joo Kyung Park; Min A Kim; Gyeong Hoon Kang; Sun-Whe Kim; Marco Del Chiaro; Godefridus J Peters; Giuseppe Giaccone
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

8.  Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.

Authors:  Hiromitsu Hatakeyama; Haixia Cheng; Pamela Wirth; Ashley Counsell; Samuel R Marcrom; Carey Burton Wood; Paula R Pohlmann; Jill Gilbert; Barbara Murphy; Wendell G Yarbrough; Deric L Wheeler; Paul M Harari; Yan Guo; Yu Shyr; Robbert J Slebos; Christine H Chung
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

Review 9.  MiRNAs and cancer.

Authors:  Rosa Visone; Carlo M Croce
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

10.  Pathogenesis and treatment of neoplastic diseases of the papilla of Vater: Kausch-Whipple procedure with lymph node dissection in cancer of the papilla of Vater.

Authors:  Hans G Beger; F Chikh Thorab; Z Liu; N Harada; B M Rau
Journal:  J Hepatobiliary Pancreat Surg       Date:  2004
View more
  49 in total

Review 1.  Prospects of miRNA-based therapy for pancreatic cancer.

Authors:  Priya Pai; Satyanarayana Rachagani; Chandrakanth Are; Surinder K Batra
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

2.  MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.

Authors:  Weihua Chang; Menggang Liu; Jianhua Xu; Hangwei Fu; Bo Zhou; Tao Yuan; Ping Chen
Journal:  Tumour Biol       Date:  2016-09-16

Review 3.  New targeted therapies in pancreatic cancer.

Authors:  Andrada Seicean; Livia Petrusel; Radu Seicean
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 4.  Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.

Authors:  Satyanarayana Rachagani; Muzafar A Macha; Nicholas Heimann; Parthasarathy Seshacharyulu; Dhanya Haridas; Seema Chugh; Surinder K Batra
Journal:  Adv Drug Deliv Rev       Date:  2014-10-23       Impact factor: 15.470

5.  MicroRNA-212 targets FOXA1 and suppresses the proliferation and invasion of intrahepatic cholangiocarcinoma cells.

Authors:  Lei Zhu; Feizhou Huang; Gang Deng; Wanpin Nie; Wei Huang; Hongbo Xu; Shaopeng Zheng; Zhongjie Yi; Tao Wan
Journal:  Exp Ther Med       Date:  2016-10-19       Impact factor: 2.447

6.  Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression.

Authors:  Q Xu; L-Z Liu; Y Yin; J He; Q Li; X Qian; Y You; Z Lu; S C Peiper; Y Shu; B-H Jiang
Journal:  Oncogene       Date:  2015-02-23       Impact factor: 9.867

Review 7.  MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.

Authors:  Marion Gayral; Sébastien Jo; Naima Hanoun; Alix Vignolle-Vidoni; Hubert Lulka; Yannick Delpu; Aline Meulle; Marlène Dufresne; Marine Humeau; Maël Chalret du Rieu; Barbara Bournet; Janick Sèlves; Rosine Guimbaud; Nicolas Carrère; Louis Buscail; Jérôme Torrisani; Pierre Cordelier
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

8.  DNMT1 is regulated by ATP-citrate lyase and maintains methylation patterns during adipocyte differentiation.

Authors:  Tatiana Londoño Gentile; Chao Lu; Peter M Lodato; Sarah Tse; Scott H Olejniczak; Eric S Witze; Craig B Thompson; Kathryn E Wellen
Journal:  Mol Cell Biol       Date:  2013-07-29       Impact factor: 4.272

Review 9.  MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers.

Authors:  Muzafar A Macha; Parthasarathy Seshacharyulu; Shiv Ram Krishn; Priya Pai; Satyanarayana Rachagani; Maneesh Jain; Surinder K Batra
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

10.  A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.

Authors:  Satoshi Nishiwada; Masayuki Sho; Jasjit K Banwait; Kensuke Yamamura; Takahiro Akahori; Kota Nakamura; Hideo Baba; Ajay Goel
Journal:  Gastroenterology       Date:  2020-05-04       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.